Victory Capital Management Inc Myovant Sciences Ltd. Transaction History

Victory Capital Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 04, 2021	SELL	$20.46 - $25.18 $35 Million - $43 Million	-1,709,225 Closed	0 $0
Q4 2020 Feb 01, 2021	SELL	$13.8 - $27.62 $1.03 Million - $2.06 Million	-74,694 Reduced 4.19%	1,709,225 $47.2 Million
Q3 2020 Nov 09, 2020	SELL	$14.05 - $22.6 $1.47 Million - $2.37 Million	-104,774 Reduced 5.55%	1,783,919 $25.1 Million
Q2 2020 Aug 07, 2020	SELL	$7.34 - $20.84 $3.98 Million - $11.3 Million	-542,788 Reduced 22.32%	1,888,693 $38.9 Million
Q1 2020 May 04, 2020	SELL	$6.55 - $14.76 $243,935 - $549,691	-37,242 Reduced 1.51%	2,431,481 $18.4 Million
Q4 2019 Feb 06, 2020	SELL	$4.2 - $19.21 $88,914 - $406,675	-21,170 Reduced 0.85%	2,468,723 $38.3 Million
Q4 2019 Feb 04, 2020	SELL	$4.2 - $19.21 $876,430 - $4.01 Million	-208,674 Reduced 7.73%	2,489,893 $31.6 Million
Q3 2019 Nov 12, 2019	BUY	$5.19 - $9.46 $2.21 Million - $4.04 Million	426,554 Added 18.77%	2,698,567 $14 Million
Q2 2019 Aug 15, 2019	BUY	$8.69 - $25.0 $12.4 Million - $35.7 Million	1,429,770 Added 169.76%	2,272,013 $20.6 Million
Q1 2019 May 03, 2019	BUY	$16.83 - $24.45 $14.2 Million - $20.6 Million	842,243 New	842,243 $20.1 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.